Clinical trial
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients…
NCT00055731 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00055731 |
|---|---|
| Title | Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse |
| Official title | Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse |
| Lead sponsor | UNICANCER, Other |
| Collaborators | Sanofi Industry AstraZeneca |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | bicalutamide, Goserelin Acetate, docetaxel, Estramustine phosphate sodium, acetylsalicylic acid, conventional surgery, radiation therapy |
| Enrollment | 413 |
| Start date | Nov 14, 2002 |
| Primary completion | Dec 21, 2010 |
| Completion | Dec 31, 2022 |
| First posted | Mar 7, 2003 |
| Last update posted | Jan 18, 2023 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: